2015 Company Overview
Delivering Transformational Medicines to Patients
At Bristol-Myers Squibb we have the potential for rapid and sustained growth ...
for fundamentally transforming the way cancer is treated ... and for helping even more patients
in need with our diverse portfolio of innovative medicines.
2015 KEY FACTS
CHIEF EXECUTIVE OFFICER Giovanni Caforio, M.D.
2015 Bristol-Myers Squibb Overview
2
BUSINESS Biopharmaceuticals
WEB ADDRESS www.bms.com
NYSE LISTING BMY
NET SALES $15.9 billion in 2014
R&D INVESTMENT $4.5 billion in 2014
NUMBER OF EMPLOYEES 24,000
Delivering Transformational
Medicines to Patients
This is an important moment for Bristol-Myers Squibb and the patients we serve.
Building on our success over the past few years, we are beginning an exciting new
chapter – one characterized by the opportunity for growth, for leading a transformation
in the way cancer is treated and for strengthening and expanding our diversified
portfolio of specialty medicines.
And we are starting this next chapter from a position of strength. We have an established, proven strategy. We have a strong portfolio of marketed products. We have
a promising pipeline and exceptional talent.
Over the next five years, we expect growth to come primarily from Opdivo (nivolumab)
and Eliquis (apixaban), with important contributions from the rest of our existing portfolio of innovative medicines. With Opdivo, we will leverage our leadership position in
Immuno-Oncology, and our development program is extremely broad, with a number
of ongoing studies across many tumors. With Eliquis, given the breadth of its label and
the strength of its prescription trends, we are very encouraged and look to build on our
momentum. And regarding the rest of our marketed products, trends are good, and we
have the right resources in place to continue to compete and grow.
Longer term, we are committed to a diversified portfolio. This starts with and includes
diversification within Immuno-Oncology into new mechanisms and new combinations
as well as in other key therapeutic areas, such as fibrosis, heart failure, Immunology
and certain genetically defined diseases.
Taken together, we are well-positioned to build on and further strengthen our leadership
position within the industry and deliver transformational medicines to our patients.
2014 GLOBAL SALES BY REGION
49% ]
21% ]
7%]
EUROPE
includes Russia and Turkey
REST OF THE WORLD
includes Japan (6%), China (4%)
OTHER
includes royalties and other
alliance-related revenues for
products not sold by our regional
commercial organizations
3
2015 Bristol-Myers Squibb Overview
23% ]
UNITED STATES
includes Puerto Rico
Evolving Our
Business Model
Our Commercial and R&D organizations share a common
purpose: to accelerate innovation in areas of high unmet
medical need, and offer meaningful and transformational
improvements in the lives of patients.
A number of principles have continued to guide efforts
to build a “benchmark” Commercial organization that is
able to deliver market-leading performance while bringing
the results of innovative science to health care providers
and their patients. First, enhancing our external focus
helps drive competitiveness and create value for all our
stakeholders. It also helps us make necessary choices
and allocate the right resources appropriately. Second,
speeding therapies to patients requires an emphasis
on simplification, including streamlining governance
and decision-making. Cooperation is key to increasing
efficiency and effectiveness. Third, engaging, enriching
and empowering our workforce will improve performance
across geographies and functions, ensuring meaningful
interactions with customers and the right strategic and
operational alignments around key growth drivers and
therapies in development.
2015 Bristol-Myers Squibb Overview
4
Follow Bristol-Myers Squibb
on Social Media
Our R&D Strategy
The evolution of Bristol-Myers Squibb’s R&D strategy has focused
on exploring disease areas of highest unmet medical need where
the company can bring the greatest value to patients. The company has continued to advance its late-stage pipeline and current
growth drivers while increasing investment in Immuno-Oncology,
an area of significant potential, and continuing to focus on targeted
oncology research, including antibody drug conjugate programs.
In addition to oncology, research efforts are concentrated in
cardiovascular disease (with a specific focus on heart failure),
immunoscience, fibrotic diseases and genetically defined diseases.
During 2014, programs in each of these areas advanced drugs in
development, many first- or best-in-class, and some potentially
transformational in nature. Each therapeutic area relies on a mix of
internal discovery as well as complimentary external collaborations
to help deliver potential therapies to patients.
2014/2015 RECENT COLLABORATIONS
Northwestern
California Institute for
Biomedical Research (Calibr)
Ono Pharmaceutical and
Kyowa Hakko Kirin
Celgene
Rigel Pharmaceutical
Celldex Therapeutics
Eli Lilly
The Medical University
of South Carolina
Five Prime Therapeutics
uniQure
Flexus
Incyte
University of Texas MD
Anderson Cancer Center
5
2015 Bristol-Myers Squibb Overview
Bavarian Nordic
“
Our goal is to continue to accelerate the translation of scientific knowledge
and insights into the next wave of potentially transformational medicines
for patients with serious diseases.
”
Delivering Future Growth
–Francis Cuss, MB BChir, FRCP
Executive Vice President and Chief Scientific Officer
DEVELOPMENT PORTFOLIO BY DISEASE AREA
Elotuzumab
Ulocuplumab
(Anti-CXCR4)
Prostvac
Anti-Fucosyl GM1
REYATAZ/EVOTAZ
ELIQUIS
NULOJIX
DAKLINZA 3
IKur Inhibitor
LPA1 Antagonist
Lulizumab (Anti-CD28)
SUNVEPRA 3
Factor XIa Inhibitor
Galectin-3 Inhibitor
Anti-CD40
Beclabuvir
(NS5B Non Nuc)
PAR4 Antagonist
Anti-CD40L
HIV Attachment
Inhibitor
HIV Maturation
Inhibitor
Urelumab (Anti-CD137)
Anti-HER2
Lirilumab (Anti-KIR)
Mesothelin-ADC
BTK Inhibitor
BET Inhibitor
S1P1 Agonist
Anti-LAG3
PEG-FGF21
Genetically Defined
Diseases
Anti-eTau
Anti-Myostatin
Small Molecules
▶
Notch Inhibitors
ORENCIA
Fibrotic Diseases
▶ ▶
OPDIVO
Cardiovascular
▶
SPRYCEL
Virology
▶
YERVOY
Immunoscience
▶ ▶ ▶ ▶ ▶
Oncology
▶ ▶ ▶ ▶
▶ ▶ ▶ ▶ ▶ ▶ ▶
Immuno-Oncology
Biologics
Marketed 1
Anti-PD-L1
Phase III 2
Phase II
Data as of June, 2015
Phase I
Approved in at least one
major market (US, EU, Japan)
In Phase III development or
currently under regulatory review
3
Not approved in the U.S.
1
2
BRISTOL-MYERS SQUIBB 2014/2015 MAJOR MILESTONES
2015 Bristol-Myers Squibb Overview
6
ELIQUIS #1 novel oral anticoagulant prescribed by cardiologists
for new-to-brand patients in the U.S. and Japan
ORENCIA surpassed $1 billion in sales for the first time in the U.S.
SPRYCEL for the treatment of chronic myeloid leukemia reached
double-digit growth
YERVOY became the first Immuno-Oncology agent to demonstrate
a long-term survival benefit in patients with advanced melanoma
OPDIVO approved for metastatic melanoma in the U.S., Europe
and Japan and approved in the U.S. and Europe for treatment
of metastatic squamous non-small cell lung cancer
2015
MID YEAR Q1/Q2
Delivered
7%
sales growth
Strong growth
Yervoy
5%
Sprycel
10%
Orencia
franchise
13%
ESTABLISHING
ELIQUIS AS
MARKET-LEADER
SUCCESSFUL
LAUNCH & GROWTH
OF OPDIVO
STRONG
PERFORMANCE OF
HCV PORTFOLIO
“
ASCO 2015: Bristol-Myers Squibb,
as it has been the past couple years,
was the center of attention with its
antibody that unleashes the immune
system to fight tumors by binding
with a molecular target called PD-1.
”
–Forbes on ASCO 2015
BRISTOL-MYERS SQUIBB INVESTING IN THE FUTURE
CRUISERATH, IRELAND – announced in 2014 plans to build
a new, state-of-the-art biologics manufacturing facility
CAMBRIDGE, MASSACHUSETTS – expand presence within
hubs of scientific excellence and innovation with a new
state-of-the-art research site expected to open in 2018.
SAN FRANCISCO, CALIFORNIA – expanding the Redwood
City site with a focus on Immuno-Oncology and Biologics
Discovery pipeline
7
2015 Bristol-Myers Squibb Overview
LAWRENCEVILLE, NEW JERSEY – construction at the
Princeton Pike state-of-the-art campus started in late 2014,
expected to open by the end of 2016
Global Manufacturing
and Supply
“
Supplying a diverse product portfolio for
markets around the globe requires stateof-the-art manufacturing capabilities,
end-to-end supply chain management,
operational excellence and a passionate
team of professionals with deep scientific
and technical expertise.
”
– Lou Schmukler
President, Global Manufacturing and Supply
GMS VISION: TO BE THE INDUSTRY BENCHMARK
2015 Bristol-Myers Squibb Overview
]
]
advanced Operational Excellence/
Lean Six Sigma capabilities
]
internal network of 15 manufacturing
and process development sites
More than 6,000
colleagues worldwide,
in China, France, Ireland,
Italy, Japan, Mexico,
Puerto Rico and
the mainland U.S.
]
]
portfolio of more than 100 products
]
supplying 66 markets globally
]
8
external network of approximately
100 contract manufacturing partners
operational expertise across
multiple technology platforms
compliance with regulatory
authorities across the globe
Focusing on Health Disparities
The Bristol-Myers Squibb Foundation promotes health equity and
helps improve the health outcomes of populations disproportionately affected by serious diseases and conditions by strengthening
community-based health care worker capacity, integrating medical
care and community-based supportive services, and mobilizing
communities in the fight against disease.
The Foundation engages partners to develop, execute, evaluate
and promote innovative programs to help patients with lung cancer
in the United States; HIV and comorbid diseases such as cervical
and breast cancers and tuberculosis in sub-Saharan Africa; hepatitis B and C in China and India; veterans’ mental health in the U.S.;
and type 2 diabetes in the U.S., China and India. The Foundation
also is working to build cancer nursing capacity in Central and
Eastern Europe; and expand access to specialty care for vulnerable
populations with lung cancer, skin cancer or HIV in the U.S.
In 2014, the Foundation launched two initiatives in the U.S. to
address inequities in health care in lung cancer and access
to specialty care for underserved populations, while continuing
to expand efforts to address cancer, hepatitis B and C, and HIV
and co-morbidities around the world.
Visit www.bms.com/foundation to learn more about the Foundation
and its work around the world.
THE BRISTOL-MYERS SQUIBB FOUNDATION
skills for oncology, general practice and public
health nurses.
Specialty Care for
Vulnerable Populations
seeks to catalyze sustainable improvement and
expansion of specialty
care service delivery for
poor and minority populations in the U.S. who are
living with lung cancer,
skin cancer or HIV.
SECURE THE FUTURE
is expanding its work
in HIV and TB in subSaharan Africa to include
cervical and breast cancers, which are among the
leading killers of women in
Africa because awareness
about breast cancer is
low and awareness about
cervical cancer is virtually
unknown.
Delivering Hope is helping health care workers
and communities in China
and India effectively raise
the profile of hepatitis B
and hepatitis C, build the
capacity of health care
providers and communities to address these
diseases, and promote
disease prevention in
the hardest-hit and most
at-risk populations.
Veterans Mental Health
& Well-Being focuses
on community-based
solutions for meeting
the mental health and
community reintegration
needs of veterans,
military service members,
their families and families
of the fallen.
9
2015 Bristol-Myers Squibb Overview
Bridging Cancer Care
seeks to reduce the
burden of lung cancer
among minority and
underserved populations
living in select southeastern U.S. states with
the highest lung cancer
burden. In Central and
Eastern Europe, Bridging
Cancer Care is working
to increase capacity and
improve cancer nursing
Our Environmental Footprint
Bristol-Myers Squibb is committed to reducing our environmental
footprint throughout our discovery, development, manufacturing
and distribution processes. This focus results in more efficient,
cost-effective operations, while conserving natural resources
vital to our operations and the communities in which we operate.
Among these projects is a solar energy system recently installed
at the company’s R&D facility in Hopewell, New Jersey. The
nearly 80,000 square-foot array of photovoltaic panels, which
sits atop a parking deck, produces enough energy to power
80 homes a year and will reduce greenhouse gas emissions
by 476 tons per year.
Reducing the environmental impact of product packaging
wherever possible is a high priority. In Japan, the size of an
Orencia (abatacept) carton was reduced by 45 percent, and
for certain markets, the outer paperboard carton for Reyataz
(atazanavir sulfate) will be eliminated. With reusable cold-chain
packaging, we’ve reduced landfill waste in Australia by 100 tons
a year, earning special recognition from the Australian Packaging Covenant. New suppliers who share eco-friendly goals are
expected to incorporate similar features during product design.
RECENT SUSTAINABILITY RECOGNITION
2015 Bristol-Myers Squibb Overview
10
Rank No. 6 on Corporate Responsibility magazine’s
100 Best Corporate Citizens 2015 list
Received the U.S. Environmental Protection Agency’s
2015 ENERGY STAR Partner of the Year Award
Best of Green Schools 2014 Award for efforts to help
New Jersey’s schools become more sustainable
ZymoGenetics in Seattle, Washington, earned the U.S.
Green Building Council’s Leadership in Energy and
Environmental Design (LEED) silver certification
Our People –
The Competitive Advantage
At Bristol-Myers Squibb, we discover, develop and
deliver innovative medicines that help patients prevail
over serious diseases.
Our people are our most critical asset. We recognize
that our focused investment in their success will drive
greater outcomes for our patients, as well as have
transformative impact on our business performance –
our people are our competitive advantage.
To this end, we are committed to creating an energizing experience at Bristol-Myers Squibb – one that
is powerfully diverse and broadly inclusive and where
individuals are encouraged to exceed their potential
and inspired to make innovative contributions for
our patients and the global communities in which
we live and work.
Equally important to our success is our commitment
to personal integrity and upholding the principles
for how we conduct business, interact with our
colleagues and serve our patients every day.
Visit www.bms.com to learn more about a
rewarding career at Bristol-Myers Squibb.
7
BRISTOL-MYERS SQUIBB ACHIEVEMENTS
Ranked among the top 10 on 2015 Corporate Responsibility
magazine’s list of the 100 Best Corporate Citizens.
Best Place to Work, Glassdoor Employees’ Choice Awards
For the 18th consecutive year, recognized as one of the
2015 Working Mother 100 Best Companies
Recognized as a 2014 NAFE Top Company for Executive Women
Achieved a 100% score on the Human Rights Campaign’s
Corporate Equality Index for 10 consecutive year
11
2015 Bristol-Myers Squibb Overview
Ranked No. 4 among the 2015 World’s Most Admired Companies
in the pharmaceutical industry, by FORTUNE magazine
Bristol-Myers Squibb Company • 345 Park Avenue • New York, NY 10154-0037 • 212-546-4000 • www.bms.com
© 2015 Bristol-Myers Squibb Company. All rights reserved. 10/2015